Literature DB >> 18715933

Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations.

Yumi Mitsuya1, Vici Varghese, Chunlin Wang, Tommy F Liu, Susan P Holmes, Prerana Jayakumar, Baback Gharizadeh, Mostafa Ronaghi, Daniel Klein, W Jeffrey Fessel, Robert W Shafer.   

Abstract

T215 revertant mutations such as T215C/D/E/S that evolve from the nucleoside reverse transcriptase (RT) inhibitor mutations T215Y/F have been found in about 3% of human immunodeficiency virus type 1 (HIV-1) isolates from newly diagnosed HIV-1-infected persons. We used a newly developed sequencing method-ultradeep pyrosequencing (UDPS; 454 Life Sciences)--to determine the frequency with which T215Y/F or other RT inhibitor resistance mutations could be detected as minority variants in samples from untreated persons that contain T215 revertants ("revertant" samples) compared with samples from untreated persons that lack such revertants ("control" samples). Among the 22 revertant and 29 control samples, UDPS detected a mean of 3.8 and 4.8 additional RT amino acid mutations, respectively. In 6 of 22 (27%) revertant samples and in 4 of 29 control samples (14%; P = 0.4), UDPS detected one or more RT inhibitor resistance mutations. T215Y or T215F was not detected in any of the revertant or control samples; however, 4 of 22 revertant samples had one or more T215 revertants that were detected by UDPS but not by direct PCR sequencing. The failure to detect viruses with T215Y/F in the 22 revertant samples in this study may result from the overwhelming replacement of transmitted T215Y variants by the more fit T215 revertants or from the primary transmission of a T215 revertant in a subset of persons with T215 revertants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18715933      PMCID: PMC2573178          DOI: 10.1128/JVI.01827-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy.

Authors:  Michela Violin; Alessandro Cozzi-Lepri; Rossella Velleca; Antonella Vincenti; Salvatore D'Elia; Francesco Chiodo; Florio Ghinelli; Ada Bertoli; Antonella d'Arminio Monforte; Carlo Federico Perno; Mauro Moroni; Claudia Balotta
Journal:  AIDS       Date:  2004-01-23       Impact factor: 4.177

2.  Genome sequencing in microfabricated high-density picolitre reactors.

Authors:  Marcel Margulies; Michael Egholm; William E Altman; Said Attiya; Joel S Bader; Lisa A Bemben; Jan Berka; Michael S Braverman; Yi-Ju Chen; Zhoutao Chen; Scott B Dewell; Lei Du; Joseph M Fierro; Xavier V Gomes; Brian C Godwin; Wen He; Scott Helgesen; Chun Heen Ho; Chun He Ho; Gerard P Irzyk; Szilveszter C Jando; Maria L I Alenquer; Thomas P Jarvie; Kshama B Jirage; Jong-Bum Kim; James R Knight; Janna R Lanza; John H Leamon; Steven M Lefkowitz; Ming Lei; Jing Li; Kenton L Lohman; Hong Lu; Vinod B Makhijani; Keith E McDade; Michael P McKenna; Eugene W Myers; Elizabeth Nickerson; John R Nobile; Ramona Plant; Bernard P Puc; Michael T Ronan; George T Roth; Gary J Sarkis; Jan Fredrik Simons; John W Simpson; Maithreyan Srinivasan; Karrie R Tartaro; Alexander Tomasz; Kari A Vogt; Greg A Volkmer; Shally H Wang; Yong Wang; Michael P Weiner; Pengguang Yu; Richard F Begley; Jonathan M Rothberg
Journal:  Nature       Date:  2005-07-31       Impact factor: 49.962

3.  PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases.

Authors:  J Cline; J C Braman; H H Hogrefe
Journal:  Nucleic Acids Res       Date:  1996-09-15       Impact factor: 16.971

4.  Contribution of Taq polymerase-induced errors to the estimation of RNA virus diversity.

Authors:  M A Bracho; A Moya; E Barrio
Journal:  J Gen Virol       Date:  1998-12       Impact factor: 3.891

5.  Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.

Authors:  S Yerly; A Rakik; S K De Loes; B Hirschel; D Descamps; F Brun-Vézinet; L Perrin
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase.

Authors:  J Goudsmit; A De Ronde; D D Ho; A S Perelson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

7.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

Authors:  J M Coffin
Journal:  Science       Date:  1995-01-27       Impact factor: 47.728

8.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

9.  Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma.

Authors:  R W Shafer; D J Levee; M A Winters; K L Richmond; D Huang; T C Merigan
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

10.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.

Authors:  Annemarie M J Wensing; David A van de Vijver; Gioacchino Angarano; Birgitta Asjö; Claudia Balotta; Enzo Boeri; Ricardo Camacho; Maire-Laure Chaix; Dominique Costagliola; Andrea De Luca; Inge Derdelinckx; Zehava Grossman; Osamah Hamouda; Angelos Hatzakis; Robert Hemmer; Andy Hoepelman; Andrzej Horban; Klaus Korn; Claudia Kücherer; Thomas Leitner; Clive Loveday; Eilidh MacRae; Irina Maljkovic; Carmen de Mendoza; Laurence Meyer; Claus Nielsen; Eline L Op de Coul; Vidar Ormaasen; Dimitris Paraskevis; Luc Perrin; Elisabeth Puchhammer-Stöckl; Lidia Ruiz; Mika Salminen; Jean-Claude Schmit; Francois Schneider; Rob Schuurman; Vincent Soriano; Grzegorz Stanczak; Maja Stanojevic; Anne-Mieke Vandamme; Kristel Van Laethem; Michela Violin; Karin Wilbe; Sabine Yerly; Maurizio Zazzi; Charles A Boucher
Journal:  J Infect Dis       Date:  2005-08-15       Impact factor: 5.226

View more
  50 in total

1.  Simian immunodeficiency virus SIVmac239Deltanef vaccination elicits different Tat28-35SL8-specific CD8+ T-cell clonotypes compared to a DNA prime/adenovirus type 5 boost regimen in rhesus macaques.

Authors:  Benjamin J Burwitz; Zachary Ende; Benjamin Sudolcan; Matthew R Reynolds; Justin M Greene; Benjamin N Bimber; Jorge R Almeida; Monica Kurniawan; Vanessa Venturi; Emma Gostick; Roger W Wiseman; Daniel C Douek; David A Price; David H O'Connor
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.

Authors:  Cassandra B Jabara; Corbin D Jones; Jeffrey Roach; Jeffrey A Anderson; Ronald Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-30       Impact factor: 11.205

3.  Recombination between variants from genital tract and plasma: evolution of multidrug-resistant HIV type 1.

Authors:  Kimdar S Kemal; Christina M Ramirez; Harold Burger; Brian Foley; Douglas Mayers; Thomas Klimkait; François Hamy; Kathryn Anastos; Katarina Petrovic; Vladimir N Minin; Marc A Suchard; Barbara Weiser
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-10       Impact factor: 2.205

Review 4.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

Review 5.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

6.  Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.

Authors:  Malaya K Sahoo; Martina I Lefterova; Fumiko Yamamoto; Jesse J Waggoner; Sunwen Chou; Susan P Holmes; Matthew W Anderson; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2013-08-28       Impact factor: 5.948

7.  Exposing malaria in-host diversity and estimating population diversity by capture-recapture using massively parallel pyrosequencing.

Authors:  Jonathan J Juliano; Kimberly Porter; Victor Mwapasa; Rithy Sem; William O Rogers; Frédéric Ariey; Chansuda Wongsrichanalai; Andrew Read; Steven R Meshnick
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

8.  Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen.

Authors:  Mariacarmela Solmone; Donatella Vincenti; Mattia Carlo Felice Prosperi; Alessandro Bruselles; Giuseppe Ippolito; Maria Rosaria Capobianchi
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  Dengue Virus Evolution under a Host-Targeted Antiviral.

Authors:  Emily Plummer; Michael D Buck; Marisa Sanchez; Jason A Greenbaum; Julia Turner; Rajvir Grewal; Brennan Klose; Aruna Sampath; Kelly L Warfield; Bjoern Peters; Urban Ramstedt; Sujan Shresta
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

10.  Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization.

Authors:  William L Ince; Patrick R Harrington; Gretja L Schnell; Milloni Patel-Chhabra; Christina L Burch; Prema Menezes; Richard W Price; Joseph J Eron; Ronald I Swanstrom
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.